Postoperative pain management after craniotomy: evaluation and cost analysis

Area of Science:

• Neurosurgery
• Pain Management
• Pharmacology

Background:

• Craniotomies traditionally involve opiate use for postoperative pain, which can lead to increased costs, delayed ambulation, and altered neurological exams.
• Alternative pain management strategies are sought to mitigate these adverse effects.
• Cyclooxygenase-2 (COX-2) inhibitors offer a potential alternative due to their selective mechanism, avoiding platelet dysfunction associated with non-selective NSAIDs.

Purpose of the Study:

• To evaluate the efficacy of cyclooxygenase-2 (COX-2) inhibitors as an alternative pain management strategy in patients undergoing craniotomy.
• To compare pain control, length of stay, and hospitalization costs between patients receiving narcotics alone versus narcotics plus a COX-2 inhibitor.

Main Methods:

• A randomized, single-blinded prospective study was conducted.
• Twenty-seven patients were enrolled and randomly assigned to either a control group (n=13) receiving narcotics or an experimental group (n=14) receiving a COX-2 inhibitor plus narcotics.

Main Results:

• The group receiving COX-2 inhibitors alongside narcotics demonstrated statistically significant lower visual analog scale (VAS) pain scores.
• The COX-2 inhibitor group experienced a shorter length of hospital stay and reduced overall hospitalization costs compared to the narcotics-only group.
• Narcotic consumption was also lower in the COX-2 inhibitor group.

Conclusions:

• Scheduled administration of COX-2 inhibitors in addition to narcotics can enhance postoperative pain management following craniotomy.
• This multimodal approach may lead to improved pain control, reduced side effects from narcotics, earlier patient mobilization, and decreased healthcare expenditures.
• COX-2 inhibitors represent a safe and effective adjunct for neurosurgical pain management.